Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
Nivolumab plus ipilimumab versus sunitinib for first-line... | ResearchHub
Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial
0
Authors
Laurence Albigès
19 more
Laurence Albigès
•
Nizar Tannir
17 more
•
Robert Motzer
Published
January 1, 2020
Paper
Conversation
0
Reviews
0
Bounties
0
Sign in to comment
Add a comment...
Best
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
ESMO Open
Topics
Medicine
Cancer Oncology
Internal Medicine
Gastroenterology
Pulmonary And Respiratory Medicine
Show all topics
DOI
10.1136/esmoopen-2020-001079
License
CC-BY-NC
Other Formats
PDF
Supporters
Support the authors with ResearchCoin
Tip RSC
Journal
ESMO Open
Topics
Medicine
Cancer Oncology
Internal Medicine
Gastroenterology
Pulmonary And Respiratory Medicine
Show all topics
DOI
10.1136/esmoopen-2020-001079
License
CC-BY-NC
Other Formats
PDF
